



October 1, 2025

PeptiDream Inc  
<https://www.peptidream.com>  
(Securities Code: 4587 TSE Prime Market)

## Upcoming Conference Presentation at EANM'25

KANAGAWA, JAPAN – October 1, 2025 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today announced that members from both PeptiDream and PDRadiopharma will be presenting the Group's proprietary program PD-32766 at Annual Congress of the European Association of Nuclear Medicine (EANM'25) held in Barcelona, Spain from October 4-8, 2025.

Information on the presentation is as follows;

### **Annual Congress of the European Association of Nuclear Medicine (EANM'25)**

(October 4-8, 2025)

Location: Barcelona, Spain

M2M Track – TROP Session – Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

Title: Identification and characterization of  $^{64}\text{Cu}$ - and  $^{225}\text{Ac}$ -PD-32766, a Carbonic Anhydrase IX targeting macrocyclic peptide radiotheranostic pair for clear cell renal cell carcinoma (ccRCC)

Presentation Format: Oral Presentation (OP-208)

Date: 4:45pm-6:15pm, October 5th, 2025

### **About PD-32766**

PD-32766 is a peptide-based theranostic agent targeting carbonic anhydrase IX (CA9), currently under development by PeptiDream Group. The compound is labeled with the diagnostic radionuclide  $^{64}\text{Cu}$  and the therapeutic radionuclide  $^{225}\text{Ac}$ . CA9 is a cancer-associated cell surface antigen that is highly expressed (over 95%) in clear cell renal cell carcinoma (ccRCC), while showing minimal expression in normal tissues, making it a promising target for both diagnosis and treatment of ccRCC. PD-32766 was discovered using PeptiDream's proprietary Peptide Discovery Platform System (PDPS<sup>®</sup>), and its in vivo imaging and efficacy studies were conducted by PDRadiopharma Inc., a wholly owned subsidiary of PeptiDream.

### **About PeptiDream Inc.**

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet

medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit [www.peptidream.com/en/](http://www.peptidream.com/en/)

### **About PDRadiopharma**

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/en/>

### **Inquiries:**

#### **PeptiDream Inc.**

Contact: Yuko Okimoto, IR & Public Affairs

Email: [info@peptidream.com](mailto:info@peptidream.com)